Literature DB >> 25465459

Langerhans cell histiocytosis presenting as hypothyroid goitre: a unique presentation.

Krishna Chaitanya Marupudi1, Suman S Karanth1, Joseph Thomas2.   

Abstract

Langerhans cell histiocytosis (LCH) is a disease involving the antigen presenting cells, which can range from a single system involvement with an indolent course to a multisystem disease with increased morbidity. We present a rare case of LCH presenting as hypothyroid goitre that was successfully treated as per the LCH III trial protocol with a combination of vinblastine and oral prednisolone. We highlight the need for awareness of this rare presentation of LCH as a painless goitre which is often misdiagnosed as poorly differentiated thyroid carcinoma or overlooked as a benign disease. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25465459      PMCID: PMC4256651          DOI: 10.1136/bcr-2014-206760

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  The site of biosynthesis of mammalian tyrosinase.

Authors:  M SEIJI; K SHIMAO; T B FITZPATRICK; M S BIRBECK
Journal:  J Invest Dermatol       Date:  1961-11       Impact factor: 8.551

Review 2.  Solitary langerhans histiocytosis of the thyroid gland: a case report and literature review.

Authors:  Darren K Patten; Zubair Wani; Neil Tolley
Journal:  Head Neck Pathol       Date:  2011-12-24

3.  Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment.

Authors:  R M Egeler; B E Favara; M van Meurs; J D Laman; E Claassen
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

Review 4.  Drug therapy for the treatment of Langerhans cell histiocytosis.

Authors:  Kenneth L McClain
Journal:  Expert Opin Pharmacother       Date:  2005-11       Impact factor: 3.889

5.  Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.

Authors:  Helmut Gadner; Nicole Grois; Ulrike Pötschger; Milen Minkov; Maurizio Aricò; Jorge Braier; Valerie Broadbent; Jean Donadieu; Jan-Inge Henter; Robert McCarter; Stephan Ladisch
Journal:  Blood       Date:  2007-12-18       Impact factor: 22.113

6.  Langerhans cell histiocytosis of the thyroid gland.

Authors:  Kevin Lollar; Tarik Y Farrag; Dengfeng Cao; John Niparko; Ralph P Tufano
Journal:  Am J Otolaryngol       Date:  2008-03-19       Impact factor: 1.808

7.  Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.

Authors:  H Gadner; A Heitger; N Grois; I Gatterer-Menz; S Ladisch
Journal:  Med Pediatr Oncol       Date:  1994

Review 8.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 9.  Langerhans cell histiocytosis of the thyroid: a report of two cases and review of the literature.

Authors:  R J Behrens; A W Levi; W H Westra; D Dutta; D S Cooper
Journal:  Thyroid       Date:  2001-07       Impact factor: 6.568

10.  Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis.

Authors:  Michelle Phillips; Carl Allen; Paul Gerson; Kenneth McClain
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

  10 in total
  2 in total

Review 1.  Spontaneous Thyroid Hemorrhage Caused by Langerhans Cell Histiocytosis: A Case Report and Literature Review.

Authors:  Jingying Zhang; Chengchen Wang; Chuanshuai Lin; Binglong Bai; Mao Ye; Dapeng Xiang; Zhiyu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

2.  A Case Report: The Diagnosis and Therapeutic Evaluation for a Rare Disease of Langerhans Cell Histiocytosis Involving Thyroid.

Authors:  Ye-Feng Cai; Qing-Xuan Wang; Chun-Jue Ni; Si-Yang Dong; Lin Lv; Quan Li; En-Dong Chen; Xiao-Hua Zhang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.